Tirzepatide, Dual GIP GLP-1 Agonist, Pharmaceutical Peptide Raw Material

Product Description
Tirzepatide is a synthetic long-acting polypeptide raw material, appearing as white lyophilized crystalline powder with pharmaceutical purity ≥99% tested by HPLC. It is the world’s first twincretin that activates both GLP-1 and GIP receptors simultaneously, possessing synergistic metabolic advantages superior to single-target GLP-1 ingredients. Modified with fatty acid side chains to bind albumin in human plasma, it achieves ultra-long half-life to support once-weekly administration. Strict impurity control guarantees batch stability, suitable for lyophilized , pharmaceutical  preparations and biomedical laboratory research. It has complete pharmacology verification and stable solubility, widely adopted in global pharmaceutical factories for diabetes drugs and weight-loss  formulations.
Core Efficacy
Dual activation of GLP‑1 and GIP receptors works synergistically to slow gastric emptying, extend satiety time, curb cravings for high-sugar and high-fat food, naturally cut calorie intake and realize continuous healthy weight loss with remarkable fat-reducing effects on visceral fat and abdominal fat.
Regulates blood glucose in a glucose-dependent manner, promotes  secretion only when blood sugar rises, inhibits abnormal glucagon secretion, effectively stabilizes postprandial blood glucose spikes and HbA1c level, safely improves glycemic status of type 2 diabetic patients without hypoglycemia risk
Optimizes overall lipid metabolism, lowers triglycerides and bad cholesterol levels, alleviates hepatic fat deposition, improves non-alcoholic fatty liver conditions and reduces risks of metabolic syndrome and fatty liver disease.
Long-cycle efficacy design allows subcutaneous  once per week, simplifies administration schedule and greatly improves patient medication compliance compared with daily  weight-loss peptides.
Improves  sensitivity and relieves  resistance fundamentally, delaying the progression of prediabetes to confirmed type 2 diabetes for sub-health populations with impaired glucose tolerance.